Efficacy and Safety of The Farnesoid X Receptor Agonist Obeticholic Acid in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease | Paper Digest

Efficacy and Safety of The Farnesoid X Receptor Agonist Obeticholic Acid in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Gastroenterology · 2013 · Impact 8

Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro;

RELATED

Papers Patents Grants Venues Experts Cite Share Save

impact factor 8
year_of_publication 2013
source Gastroenterology

AI Reader
upload a document and start your AI-powered reading

AI Writer
you focus on what matters the most, we handle the rest

Daily Digest
get customized highlights of the latest research & news